A
Anil Fernandes
Mumbai-based Indian pharma consultant (SLIM Solutions) and former CXO at Integrace Healthcare, Abbott, and Sanofi, guest on My Pharma Reviews podcast.
3
APPEARANCES
1
PODCASTS
024
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
Sep 19, 2026
Episode 6: When Does a Pharma Platform Become Real?
S
0:00Salil KalyanpurHOST
Tell me something you know let's say a year from now 12 months from now what is the signal that will tell you that this specific platform strategy has is working versus you know I wouldn't call it failure but it is stalling you know it has to grow at a at a particular rate because they've like I said they've got just a three to five year runway before they start looking for the next seller so we have to start looking at signals very early so maybe 12 months down would you think about signals that CXO should look for which tells them whether this bet is working or not?
A
0:38Anil FernandesGUEST
I think the first 12 months is clearly the mirror, which tells you where you stand.
A
0:45Anil FernandesGUEST
And it really gives you an indicator of the path that you have set for yourself in terms of that value creation bridge that I just mentioned right at the outset of this podcast.
A
0:57Anil FernandesGUEST
And therefore, not just the CEO or the investors, but I think the rank and file of the organization should pull their might you know behind the vision and the mission aligning every part of their work to the overall objective why they are doing what they are doing so that critically you know we achieve our objectives at the same time looking at our value proposition which is going to be the co-driver of how we are going to connect and create strong sentiments in the mind of our customers to build stronger value over a period of time So the indicators, I think these are critical indicators.
9 MINS LATER
S
10:53Salil KalyanpurHOST
And so, you know, would you see any of that rate of acquisitions getting affected because of the things that you just said?
Episode 5: From Pharma Platform to Healthcare Platform?
S
5:09speaker_0HOST
You know, so you still think that this fits the same platform thesis as Integration Khoye or do you think this is a fundamentally different bet that is dressed up in the same language? Yeah, I like your choice of words.
A
5:34Anil FernandesGUEST
So as you said that it's building a new organization identity, it's setting up a platform.
A
5:41Anil FernandesGUEST
So what is happening now with the potential addition of a Koi and let's keep a tab on that as to how it pans out and what happens.
S
9:36speaker_0HOST
You know, so we've got Warburg building fresh from Integrase, Koye and soon Manish and Universal Nutri Science under a new CEO versus Chris Capital, which has taken control of an existing listed entity Novartis India and and over here I think I should I should give a disclaimer saying that you know both Anil and I are talking about Novartis and Novartis this does not mean the Novartis AG entity but this means the spun-off Novartis India entity which was sold to Chris capital sometime in June or July so just just that disclaimer we are we have to use Novartis India because the that entity is not called anything else of now so anyway back to my question I think you know Warburg has a different way of building a playbook whereas Chris capital has taken control of an existing listed entity called Novartis India and then bolting on assets like many press Excel trademarks you know so Anil do you think these are the same strategy wearing different clothes or fundamentally different risk profiles which which both these private equity players are looking at and which would you advise a mid cap promoter to attempt
Episode 4: The Platform Can’t Outrun Its Culture
A
1:45Anil FernandesGUEST
And when you talked about the screening checklist, I think one of the most important screening checklists is to understand the culture of the organization that you're potentially interested in.
A
1:54Anil FernandesGUEST
Now, culture is something that's invisible, right? So you need the insight to really get deep into the kind of culture and look at the potential implications of this culture in terms of seeing how well aligned it is matched to your value systems and to your culture or whether it's really mismatched.
A
2:13Anil FernandesGUEST
So we've had numerous examples even in a pharma industry of large acquisitions with a new culture actually getting into the system.
A
2:22Anil FernandesGUEST
And then you realize that you require a lot of time to set right the cultural mismatch.
A
2:27Anil FernandesGUEST
And in the period that it takes to set right and do the firefighting, you have actually lost the ground for building value in that initial stage because most of your efforts and most of your time has actually gone in terms of firefighting over things that could have been better handled to a proper due diligence in the past and therefore taking course corrections proactively rather than realizing it once it is integrated into your system.
6 MINS LATER
S
8:57Salil KalyanpurHOST
I don't know if you can expand that much, but then as much as possible, if you can talk about where these platform beds could go wrong, I'm sure it will give a very good contrast to the audience to understand whether this actually works or not.